Stryker Corp. is selling off the troubled product line of bone growth therapies that are made by its Hopkinton-based subsidiary Stryker Biotech LLC to Olympus Corp. for $60 million.

According to Michigan-based Stryker Corp., the entire OP-1 product family, which includes OP-1 Implant, OP-1 Putty, Opgenra and Osigraft, will be sold to Olympus. The deal includes the manufacturing facilities for the OP-1 products in Lebanon, N.H.

SOURCE